

Ubie secures \$26.2 M to fuel business growth in Japan & US

22 August 2022 | News

Bringing unprecedented medical experience by strengthening partnerships with pharmaceutical companies in Japan and US

Japan-based startup Ubie, Inc. has raised \$26.2 million in the 1st round of Series C funding. New investors in the round include Norinchukin Capital Co., Ltd., NVenture Capital Limited (wholly owned subsidiary of NEC Capital Solutions Limited), The Dai-ichi Life Insurance Company, Limited, and Egg FORWARD, Inc., while existing investors include SUZUKEN CO., LTD. To date, Ubie has raised \$59.8 million.

Ubie is one of the few startups in the world with a medical data platform that has direct contact with both patients and medical institutions. Ubie offers two services that focus on the "medical questionnaire" as a gateway to healthcare, using artificial intelligence (AI) as its core technology.

Series C funding will be used to fuel business growth in Japan and the US to build a medical data platform that connects patients, medical institutions, and pharmaceutical companies.

Ubie Co-founder and CEO Yoshinori Abe, MD, said: "Not only in Japan, but also in other countries, the current healthcare system is suffering from various losses due to the fragmentation of information held by patients, medical institutions, and pharmaceutical companies. This fundraising aims to accelerate collaboration with pharmaceutical companies and create an unprecedented consumer-centered medical experience utilizing Ubie's data platform. Ubie already has business with more than 20 major pharmaceutical companies in Japan and other countries, and this brings Ubie closer to realizing its mission 'To develop a healthcare guide for everyone,' both in Japan and the US."